Natural history of superficial head and neck squamous cell carcinoma under scheduled follow-up endoscopic observation with narrow band imaging: retrospective cohort study by unknown
RESEARCH ARTICLE Open Access
Natural history of superficial head and neck
squamous cell carcinoma under scheduled
follow-up endoscopic observation with
narrow band imaging: retrospective cohort
study
Hiroshi Nakamura1, Tomonori Yano1*, Satoshi Fujii2, Tomohiro Kadota1, Toshifumi Tomioka3, Takeshi Shinozaki3,
Ryuichi Hayashi3 and Kazuhiro Kaneko1
Abstract
Background: The incidence rate has been increasing for superficial head and neck squamous cell carcinoma
(HNSCC) discovered through surveillance endoscopic study using narrow band imaging (NBI), a procedure mainly
used for high-risk patients with esophageal squamous cell carcinoma (ESCC). However, there are few reports on the
natural history of superficial HNSCC. The aim of this retrospective study was to investigate the natural history of
superficial HNSCC.
Methods: From January 2007 to December 2012, 535 consecutive histologically confirmed superficial HNSCCs at
the oropharynx, hypopharynx, or larynx in 319 patients were detected by endoscopic surveillance examination by
using NBI. Of those, 20 untreated and observed lesions fulfilled the eligibility criteria and were analyzed in this
study.
Results: Twenty lesions from 17 patients were analyzed. All patients were men ranging from 52 to 86 years of age,
with a median age of 69 years. The median endoscopic follow-up period was 20 months (range, 6–71); 17 lesions
progressed in size. In this study, four patients died; the causes of death were synchronous ESCC, synchronous
HNSCC, acute myocardial infarction, and unknown causes. No patient died from progression of superficial HNSCC.
Conclusions: Most superficial HNSCC has the potential to change progressively. Therefore, superficial HNSCC
should be detected at an early stage and be treated less invasively, such as with endoscopic resection or partial
resection.
Background
Observation using a narrow band imaging (NBI) endo-
scope with magnified view makes it possible to visualize
microvascular irregularities such as abnormalities of the
intra-papillary capillary loop (IPCL). Several prospective
randomized studies using this imaging technique have
shown that the detection rate of superficial squamous cell
carcinoma of the larynx and pharynx is enhanced [1–3].
Almost all superficial head and neck squamous cell car-
cinoma (HNSCC) can be cured with favorable prognosis
by endoscopic resection (ER) or partial resection [4].
The synchronous or metachronous occurrence of
esophageal squamous cell carcinoma (ESCC) and other
HNSCCs is observed frequently; the former and latter
rates are reported to be 14–83 % and 28 %, respectively
[5, 6]. It is difficult to decide on a treatment course in
such patients with synchronous or metachronous can-
cers. Generally, treatment for more advanced cancer
takes precedence over that for other cancers when
multiple synchronous cancers are detected at once.
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Therefore, treatment for superficial HNSCC is generally
planned after concomitant advanced cancers have
achieved a cure. Also, superficial HNSCC can be observed
alone without any therapeutic intervention in cases where
patients have an intolerable physical condition or con-
comitant further advanced stage of ESCC or HNSCC at
other sites. However, there have been few reports regard-
ing the natural history and prognosis of superficial
HNSCC; therefore, therapeutic strategies are not well
established. The aim of this retrospective study is to inves-
tigate the natural history of superficial HNSCC.
Methods
Patients
From January 2007 to December 2012, consecutive
superficial HNSCCs were detected by oral endoscopic
examination using NBI in high-risk patients who had
prior or present HNSCC and ESCC. These lesions were
located in the oropharynx, hypopharynx, and larynx, and
were histologically confirmed. For these lesions, we ana-
lyzed the cohort that met the following eligibility cri-
teria: 1) the lesion was the primary, 2) the lesion
diameter was 20 mm or less, 3) the lesion was supposed
to be clinically localized in the superficial mucosal re-
gion, 4) there was no lymph node or distant metastasis,
5) the initial treatment plan for HNSCC was observa-
tion, or planned ER if concomitant cancers, such as
ESCC or HNSCC, had achieved a cure, 6) at least one
follow-up endoscopic observation was performed after
detection and the follow-up period was longer than
6 months, 7) there was no systemic chemotherapy for
any cancer, and 8) there was no prior radiotherapy that
involved the head and neck region.
Written informed consent was provided by the pa-
tients before all examinations and interventions. This is
a retrospective study at a single institution, and the
study protocol was approved by the institutional review
board of the National Cancer Center on 23 March 2015
(approved clinical study number 2014–368) and was
undertaken in conformity with the provisions of the
Declaration of Helsinki. All information was collected
from the database of our hospital or the patients’ med-
ical charts and reports.
Endoscopic examination
Before endoscopic observation, 17.5–35 mg pethidine
hydrochloride with or without 20 mg scopolamine butyl-
bromide was administered intravenously to patients who
did not have any contraindications to pethidine and sco-
polamine. For all patients, findings of NBI (GIF H260Z,
GIF H260, GIF Q260; Olympus Medical Systems Co.,
Tokyo, Japan) were obtained at the initial surveillance or
follow-up examination for HNSCC by oral esophago-
gastric-duodenoscopic study (Fig. 1). The endoscopic
images were retrospectively examined in detail with re-
spect to location, macroscopic type, and size of each le-
sion. Lesion size was estimated by using forceps at a
width of 6 mm when open (Radial Jaw [Boston Scien-
tific, MA, USA]). The macroscopic type of lesion was
classified according to the Japanese Classification of
Esophageal Cancer (10th edition) [7]. Submucosal
invasion was defined by endoscopic findings, such as
enlargement of diameter, enhancement of thickness,
change of protrusion and depression in the lesion, and
the irregularity of the surface.
Histological diagnosis
All the biopsy tissue specimens were fixed with formalin
and embedded in paraffin to make a paraffin block. Thin
4 μm sections were cut from the blocks and stained with
hematoxylin and eosin. Then, a histological diagnosis
was performed by experienced pathologists by observing
the sections under microscopic examination according
to the World Health Organization classification of tu-
mors (head and neck tumor, 2005). Superficial HNSCC
in this study was defined as a lesion without invasion to
the muscularis propria [8].
Follow-up
Superficial HNSCC was followed-up with NBI endos-
copy and physical examinations at 3–6 month intervals.
In every endoscopic examination, we checked character-
istics of lesions and measured depths of invasion and
tumor diameters.
In our institution, superficial HNSCCs confirmed his-
tologically are treated by ER or surgical resection in
principle. Therefore, most superficial HNSCCs are
treated when detected; however, some superficial
HNSCCs are observed without any treatment when
there are concomitant cancers or patients’ general condi-
tions are poor. Moreover, some patients had dysphagia
due to prior treatment for pharyngeal cancer. In these
cases, superficial HNSCCs were observed without any
treatment out of concern for worsening of patient swal-
lowing ability. We continuously evaluated both the sta-
tus of superficial HNSCC and that of concomitant
cancers or the general condition of patients at each
follow-up thereafter, and discussed the validity of treat-
ment for superficial HNSCC. Furthermore, if a lesion in-
filtrated into the muscularis propria or deeper, or had
lymph node and distal organ metastasis, we considered
treating the lesion with more invasive therapy, such as
surgical resection with lymph node resection or chemo-
radiotherapy (CRT).
Progression of lesion was defined by enlargement of
tumor diameter and volume verified endoscopically. The
lesions were divided into progression and non-progression
groups, and then we compared patients’ age, lesion size,
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number of submucosal invasions, endoscopic follow-
up period, and number of endoscopic examinations in
each group. The endoscopic follow-up period was de-
fined as the time between initial diagnosis and final
endoscopic examination. The number of endoscopic
examinations was counted as those that were per-
formed between the initial diagnosis and the detection
of enlargement.
Statistics
The time to progression was measured from the date
of diagnosis and the first date of enlargement of
tumor diameter or volume verified endoscopically,
and the tumor progression time curve was generated
with the Kaplan-Meier method. This statistical ana-
lysis was done with SPSS 22.0 (IBM, Armonk, New
York, USA).
Results
Characteristics of patients and lesions
Of the 535 consecutive lesions in 319 patients, 20 lesions
(3.7 %) in 17 patients were enrolled and analyzed (Fig. 2).
Of the 151 HNSCC lesions that underwent observation,
44 lesions did not receive follow-up endoscopy. The main
reason for study drop out was due to the status of
concomitant advanced cancer. Of the total lesions, 55 re-
ceived systematic chemotherapy for cancer in other or-
gans, or radiotherapy for another concomitant pharyngeal
Fig. 1 Endoscopic finding of superficial HNSCC in right piriform sinus. a White light imaging. Detection of lesion was difficult. b Narrow band
imaging. Detection of lesion was easy as brownish area
Fig. 2 Patient enrollment in this study. Most lesions were treated by endoscopic resection, surgery, chemotherapy, and/or radiation. In the 151
untreated lesions observed, 20 lesions in 17 patients met the eligibility criteria. HNSCC, head and neck squamous cell carcinoma
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cancer. Therefore, we excluded these lesions due to
the influence of treatment. The characteristics of pa-
tients and lesions are listed in Table 1. All 17 patients
were men, and the median age was 69 years, ranging
from 52 to 86 years. Of the 20 lesions, three were in
the oropharynx, 12 were in the hypopharynx, and five
were in the epiglottis. In regards to the macroscopic
type of individual lesions, type 0-IIb was dominant.
All lesions were endoscopically diagnosed as squa-
mous cell carcinoma in situ. The median tumor size
was 10 mm in diameter (range, 3–20 mm). Synchron-
ous ESCCs, comprised of two early stage and five
advanced stage, were present in seven patients. Syn-
chronous HNSCCs, comprised of six superficial and
one advanced stage at another site, were present in
seven patients. Eight patients had prior ESCCs: three
patients treated by ER, two patient treated by surgical
resection, and three patients treated by CRT. In con-
trast, seven patients had prior HNSCCs: two patients
treated by ER and five patients treated by surgical
resection.
Clinical course
The clinical course of all lesions is displayed in Fig. 3.
The median endoscopic follow-up period was 20 months,
ranging from 6 to 71 months (Table 2). Of the 20 le-
sions, 17 progressed during the follow-up period. Of the
20 lesions, eight lesions were treated. Six of the eight le-
sions were treated by ER after the median endoscopic
follow-up period of 14 months (range: 8–42 months).
Whereas, only one lesion that progressed after the
13 month observation period required treatment with
surgical resection. That lesion was pathologically diag-
nosed with a surgical resected specimen as showing sub-
mucosal invasion. Another lesion was treated with CRT at
81 months after initial diagnosis. As shown in Fig. 4, the
lesion was located in the hypopharynx, and its size was
5 mm. The endoscopic finding of progression and sub-
mucosal invasion appeared at 29 months and 58 months
after commencement of follow-up, respectively. Of the
eight treated patients, one patient died of synchronous
ESCC at the conclusion of the study. Furthermore, two of
the 20 lesions in two patients were treated with systemic
chemotherapy, not for superficial HNSCC, but for ad-
vanced cancer in other organs at 22 and 24 months after
initial diagnosis of superficial HNSCC.
The remaining 10 lesions in seven patients did not re-
ceive any treatment for superficial HNSCC. The clinical
course of these lesions is displayed in Fig. 5. All lesions
progressed after a median period of 30 months (range:
11–53). Seven of 10 lesions had endoscopic findings of
submucosal invasion. Eight of nine lesions continuously
progressed thereafter, and the other lesion followed up
Table 1 Characteristics of superficial HNSCC (n = 17) and lesions





Age, median (range), years 69 (52–86)
Synchronous cancer, n (%)
HNSCC 7 (41)
ESCC 7 (41)
Prior cancer, n (%)
HNSCC 7 (41)
ESCC 8 (47)
Lesion size, median (range), mm 10 (3–20)
Macroscopic type, n (%)
Type 0-IIa 8 (40)
Type 0-IIb 10 (50)
Type 0-IIc 1 (5)





HNSCC head and neck squamous cell carcinoma, ESCC esophageal squamous
cell carcinoma
Fig. 3 Clinical course of all lesions
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with endoscopy after progression was stable. In these pa-
tients, three patients died: one patient died of acute
myocardial infarction, one patient died of synchronous
ESCC, and one patient suddenly died of unknown
causes. The other four patients remained alive, although
no treatment had been performed.
The Kaplan-Meier curve of tumor progression time in
all lesions is displayed in Fig. 6. All lesions progressed in
30 months of endoscopic follow-up and half of the le-
sions progressed in 11 months.
Characteristics of progression and non-progression
lesions
The characteristics of patients and those lesions with
progression and non-progression are compared in
Table 3. The median endoscopic follow-up periods of
the progression and non-progression groups were
21 months (range, 6–71) and 13 months (range, 6–20),
respectively (Table 4). In the progression group, the me-
dian period from diagnosis to appearance of lesion en-
largement was 10 months (range, 3–29). The size of one
lesion doubled at the earliest at 3 months after diagnosis.
Endoscopic findings revealed submucosal invasion in
nine lesions during follow-up and the median time to
appearance was 21 months (range, 11–58).
Discussion
To our knowledge, this is the first study examining the nat-
ural history of superficial HNSCC. In this study, all lesions
were diagnosed with NBI endoscopy and histologically con-
firmed with findings from biopsy specimens, and most of
them progressed naturally. Takemura et al., reporting on
the natural history of flat-type brownish lesions 5 mm or
less in size in the oropharynx, found that the lesions did
not change during 2 years of follow-up. However, patho-
logical diagnosis was not performed and all lesions were de-
scribed based on endoscopic findings alone [9]. Brownish
areas of the pharynx vary from inflammation to invasive
SCC. We previously reported the existence of basal cell
hyperplasia (BCH), which is recognized as a small brownish
area with NBI, but does not fulfill the pathological diagnos-
tic criteria of neoplastic lesions such as SCC or dysplasia
[8]. Most BCH in our previous report were 5 mm le-
sions or smaller. In contrast, most lesions enrolled in
the present study were 5 mm or larger when de-
tected. While most lesions were flat type, 85 % of
Table 2 Endoscopic findings and clinical courses of the patients
(n = 17) and lesions (n = 20) described in Table 1
Endoscopic follow-up period, median (range), month 20 (6–71)
Change of lesion size, n (%)
Progression 17 (85)
Non-Progression 3 (15)
Treatment for HNSCC, n (%) 8 (40)
Endoscopic resection 6 (30)
Surgical resection 1 (5)
Chemoradiotherapy 1 (5)
Death, n (%) 5 (29)
Due to progression of superficial HNSCC 0 (0)
HNSCC head and neck squamous cell carcinoma
Fig. 4 Endoscopic and pathological imaging of a progression lesion. a Brownish area with irregular IPCL in left pyriform sinus at diagnosis. The
diameter was 5 mm. b The photomicrograph of the biopsy specimen shows the histopathology of squamous cell carcinoma in situ. (Hematoxylin
and eosin staining × 20). c After 24 months. The lesion was not significantly different. d After 40 months. The lesion enlarged to 20 mm in
diameter. e After 48 months. The lesion was larger and elevated. f After 58 months. An irregular surface and thickness of the lesion appeared.
Submucosa invasion was suspected
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them progressed. Therefore, the clinical course of
superficial HNSCC confirmed histologically was differ-
ent from those of flat-type brownish micro lesions.
We believe that a 3 mm or larger superficial HNSCC
is a significant lesion that requires careful follow-up
or endoscopic intervention.
There are several reports about the depth of tumor inva-
sion. It has been reported that macroscopic classification
is related to tumor invasion. We previously reported that
submucosal invasion was found in significantly more type
0-I and type 0-IIa lesions than in other macroscopic types.
In addition to macroscopic classification, the rate of sub-
mucosal invasion increased significantly with larger tumor
size [10]. Tateya et al. also reported that all lesions of type
0-I showed submucosal invasion, and 54 % of type 0-IIa
lesions showed submucosal or muscular invasion. The
Fig. 5 Clinical course of untreated lesions
Fig. 6 The Kaplan-Meier curve of tumor progression time in all lesions
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ratio of submucosal or muscular invasion in each macro-
scopic type showed a significant difference [11]. Moreover,
Fujii et al. reported there was significant correlation be-
tween the microvascular density of pharyngeal SCC and
intra-epithelial SCC thickness and submucosal invasion
[8]. As mentioned earlier, endoscopic findings can esti-
mate tumor invasion and thickness. However, Taniguchi
et al. reported that cervical lymph nodal metastasis of
intra-epithelial SCC and submucosal invasive SCC of the
pharynx were 0 % (0/77) and 9 % (7/75), respectively. Fur-
thermore, in submucosal invasive SCC, tumor thickness
of over 1000 μm was a significant risk factor for nodal me-
tastasis and venous or lymphatic invasion [12]. As stated
earlier, there were several reports about the endoscopic
findings of submucosal invasive SCC. We decided the
treatment plan of superficial HNSCC by those endoscopic
findings. In our present study, although there were type 0-
IIa lesions, no lesions had other obvious endoscopic find-
ings indicating submucosal invasion at initial diagnosis.
Considering these findings, it is suggested that all patients
could be cured by ER. However, endoscopic findings, such
as tumor enlargement or enhanced thickness, surface
irregularity, and protrusions or depressions that suggested
submucosal invasion appeared in nine lesions at the earli-
est at 11 months after diagnosis. Moreover, one pro-
gressed lesion treated with surgical resection at 13 months
after diagnosis had invaded the submucosal layer, although
there were no endoscopic findings during the initial and
follow-up examination indicating submucosal invasion.
These lesions might have a risk of nodal metastasis, and it
might be difficult to cure only with ER or partial resection.
This fact suggests that superficial HNSCC should be
treated at an early stage, especially before tumor enlarge-
ment or appearance of endoscopic findings that suggest
submucosal invasion. It is suggested that treatment for
superficial HNSCC no larger than 20 mm commence
within 1 year, because endoscopic findings indicating sub-
mucosal invasion appeared within 1 year after initial diag-
nosis in this study.
There are several limitations of this study. First, the
median follow-up of 20 months might be insufficient to
clarify the natural history of superficial HNSCC. Al-
though 17 of the 20 lesions progressed in size during the
endoscopic follow-up period, there were no patients
who died from progression of superficial HNSCC. The
follow-up period might be too short to reveal whether the
superficial HNSCC would progress to be a cause of death.
However, we believe that superficial HNSCC could be a
cause of death because most lesions progressed to sub-
mucosal invasion in this study. Furthermore, we divided
cohorts into two groups based on whether they pro-
gressed or not. We could not identify specific characteris-
tics, such as endoscopic macroscopic type and location of
lesions, in the progression group. Also, the follow-up
period for the non-progression group was relatively short
compared to that of the progression group, and two le-
sions were treated with ER and the other lesion was ex-
posed to systemic chemotherapy in non-progression
group.
Finally, the number of patients and lesions was small
in this study. Further study with a large number of cases
and a longer follow-up period at a multicenter setting
will be required to clarify the natural history of these le-
sions and to clarify decision criteria for treatment of
superficial HNSCC.
Conclusions
This study showed that most superficial HNSCC pro-
gressed in size naturally, suggesting they should be
treated with less invasive treatment such as ER or partial
resection when they are small, if the patient’s situation
allows. Whereas, if patients have high comorbidities
such as active cancers or a physical intolerability to sur-
gery, these lesions should be carefully followed-up under
endoscopic observation.
Table 3 Characteristics in the two groups
Progression Non- Progression
n = 17 n = 3
Age, median (range), years 69 (52–86) 70 (65–75)
Lesion size, median (range), mm 10 (3–20) 15 (8–15)
Macroscopic type, n (%)
Type 0-IIa 6 (35) 2 (67)
Type 0-IIb 9 (53) 1 (33)
Type 0-IIc 1 (6) 0 (0)
Type 0-IIa + 0-I 1 (60) 0 (0)
Location, n (%)
Oropharynx 3 (18) 0 (0)
Hypopharynx 9 (53) 3 (100)
Larynx 5 (29) 0 (0)




n = 17 n = 3
Endoscopic follow-up period,
median (range), months
21 (6–71) 13 (6–20)
Number of endoscopic examinations,
median (range)
5 (1–10) 2 (2–5)
Time of tumor progression,
median (range), months
10 (3–29)
Number of submucosal invasion, (%) 9 (53)
Time to submucosal invasion, median
(range), months
21 (11–58)
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